WILMINGTON, DE — AstraZeneca’s experimental cancer drug sonesitatug vedotin reduced the risk of death by 53% in patients receiving third-line or later treatment for advanced gastric and related…
WILMINGTON, DE — AstraZeneca’s experimental cancer drug sonesitatug vedotin reduced the risk of death by 53% in patients receiving third-line or later treatment for advanced gastric and related cancers, according …
Source disclosure
This is a source-linked briefing. Read the original report from Mychesco .